Vancomycin resistance exhibited by Enterococcusfaecalis isolates V583, V586, and V587 is described. The vancomycin MICs ranged from 32 to 64 pg/ml. Although resistant to vancomycin, the isolates were susceptible to teicoplanin (MIC, O0.5 pg/ml). Such a glycopeptide susceptibility profile has not been previously described for E. faecalis. Time kill studies showed that vancomycin resistance adversely affected the synergistic activity that vancomycin and aminoglycoside combinations usually demonstrate against enterococci. However, the ability to detect vancomycin resistance varied with the susceptibility testing method used. Whereas broth
microdilution, broth macrodilution, and agar dilution methods detected resistance, disk-agar diffusion and the AutoMicrobic system Gram-Positive GPS-A susceptibility card (Vitek Systems Inc., Hazelwood, Mo.) did not.
To detect vancomycin resistance reliably and establish the incidence of such E. faecalis isolates, adjustments in some susceptibility testing methods may be necessary.
Vancomycin combined with an aminoglycoside provides effective alternative therapy for serious enterococcal infections that occur in patients who cannot tolerate the penicillin-class antibiotics usually used in combination with aminoglycosides (8, 25, 26) . Although vancomycin resistance has rarely been described (19, 22) , recent reports from Europe (10, 11, 20, 23 ; F. W. Goldstein, A. Y. Buu-Hoi, R. Williamson, and J. F. Acar, Program Abstr. 27th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 1022, 1987) indicate that such resistance among enterococci is an emerging problem.
While determining the antibiotic susceptibility profiles of several Enterococcus faecalis isolates, we encountered three isolates that, by broth microdilution, exhibited vancomycin resistance. We established the drug susceptibility profiles of these isolates and studied the abilities of various in vitro susceptibility testing methods to detect this vancomycin resistance. We also investigated the effect of vancomycin resistance on the synergistic activity usually achieved by vancomycin-aminoglycoside combinations against E. faecalis (8, 25, 26 (Pasco Gram-Positive MIC Panels; Difco Laboratories, Detroit, Mich.), the AMS GPS-A susceptibility card (Vitek Systems Inc., Hazelwood, Mo.), broth macrodilution, agar dilution, and disk-agar diffusion tests, performed by procedures outlined by the National Committee for Clinical Laboratory Standards (NCCLS) (13, 14) and the manufacturer's recommendations. After MICs were determined by broth macrodilution, MBCs were ascertained according to NCCLS guidelines (15) . By this method, drug concentrations that yielded <10 CFU on subculture were taken as the MBC. Additional tests performed with the E. faecalis isolates included the Cefinase disk for 3-lactamase production (BBL Microbiology Systems, Cockeysville, Md.) and high-level aminoglycoside resistance screens performed by using broth microdilution (Pasco Gram-Positive MIC panels) and diskagar diffusion with high-content streptomycin (300-,.g) and gentamicin (120-,ug) disks (18) .
Time kill studies. Methods outlined in a previous study were used to perform time kill tests with each enterococcal isolate (17) . The drug concentrations selected for testing, based on clinically achievable levels in blood were as follows: gentamicin, 5 ,ug/ml; streptomycin, 20 ,ug/ml; vancomycin, 10 ,ug/ml; teicoplanin, 5 ,ug/ml; and daptomycin, 10 jig/ml. Inoculated broths were incubated in an ambient atmosphere at 35°C. At 0-, 4-, and 24-h intervals after inoculation, a 0.5-ml portion was removed from each of the tubes and subjected to serial 10-fold dilutions. From each diluent tube, 0.1-ml samples were taken and plated over the entire surface of Trypticase soy blood agar plates (BBL Microbiology Systems, Cockeysville, Md.). By using the viable counts determined at each time interval, a 24-h time kill curve was established for each E. faecalis strain. Synergy was defined as a .100-fold increase in killing by a drug combination over the killing accomplished by the most active of the two drugs in the combination when tested separately (12) .
RESULTS
Both conventional testing and the AMS Gram-Positive identification cards confirmed the identities of V583, V586, and V587 as E. faecalis. All three isolates exhibited pyrrolidonylarylamidase activity, for which other vancomycinresistant gram-positive bacteria such as Pediococcus spp., Leuconostoc spp., and most Lactobacillus spp. are negative (4, 5) . Additionally, the AMS Vitek identified the isolates as E. faecalis with a 99% probability. In our experience, the AMS does not identify Leuconostoc spp., lactobacilli, and pediococci as E. faecalis (unpublished observations). Because none of these isolates exhibited motility at 30°C, the possibility that they were strains of E. gallinarum was ruled out.
The susceptibility profiles of the three isolates, as determined by broth microdilution, were the same; vancomycin, >16 ,ug/ml; penicillin, 1 ,ug/ml; ampicillin, 0.25 ,ug/ml; erythromycin, >4 jig/ml; tetracycline, .0.5 p.g/ml; chloramphenicol, 8 ,ug/ml; ciprofloxacin, 0.5 ,ug/ml; rifampin, c0.5 ,ug/ml; streptomycin, <2,000 jig/ml; and gentamicin, >2,000 ,ug/ml. Even with the lowest-potency disk used (5 ,ug) , the smallest inhibition zone obtained (11 mm) was greater than the 9-mm interpretive zone size recommended for determining vancomycin resistance (1, 13) .
The comparative activities of vancomycin, teicoplanin, and daptomycin are given in 1321, 1988) .
The glycopeptide susceptibility profiles exhibited by V583, V586, and V587 have been reported previously for E. faecium and E. gallinarum but not for E. faecalis (9, 23; Goldstein et al., 27th ICAAC). For these E. faecium and E. gallinarum strains, vancomycin MICs were 32 and 16 ,uglml, respectively, and teicoplanin MICs were 0.25 and 1 p.g/ml, respectively. In contrast, the E. faecalis isolates reported by Uttley et al. (23) were resistant to both vancomycin and teicoplanin, and the vancomycin MICs were >64 ,g/ml. Similarly, the vancomycin-and teicoplanin-resistant E. faecium strains reported by Leclercq et al. (10, 11) , also resistant to both vancomycin and teicoplanin, had vancomycin MICs that ranged from 512 to 1,024 pug/ml. The E. faecalis strain reported by Shlaes et al. (20) had vancomycin and teicoplanin MICs of 256 and 16 ,uglml, respectively. These variations in enterococcal susceptibility to vancomycin and teicoplanin indicate that differences may exist both in the modes of action of these two glycopeptides and in the mechanisms of enterococcal resistance to them. Further studies designed to investigate the physiological basis for these differences in resistance are under way.
Daptomycin MICs for these vancomycin-resistant strains were comparable to those for vancomycin-susceptible and -resistant isolates published in previous reports (7) (8) (9) (10) . The differences between daptomycin MICs obtained by broth macrodilution and those obtained by agar dilution were reproducible and may be due to possible differences in the calcium contents of the agar and broth MH media used in this study (6) . Daptomycin activity, as measured by both methods, was comparable to that reported by other investigators (2, 7, 9-11, 21, 23, 24) .
Certain evidence strongly suggests that the isolates described in the present study are the same strain. All three have the same antibiotic susceptibilities, including resistance to vancomycin but not teicoplanin. Two isolates were from the same patient (V583 and V586), and the third isolate (V587) was from a second patient whose time of stay in an intensive care unit overlapped that of the first patient. Nosocomial dissemination of enterococci has been documented (27) and may explain the isolation of these E. faecalis strains with unique glycopeptide resistance profiles from different patients. Plasmid analysis of V583 and V586 showed that, although both isolates were from the same patient, their plasmid profiles differed slightly. Of the three extrachromosomal bands observed in V583, only two were seen in V586. The plasmid profile of V587 was the same as that of V583.
The incidence of such vancomycin resistance among E. faecalis is probably quite low, but the failure of disk-agar diffusion and the AMS Vitek System, two commonly used susceptibility-testing procedures, to detect this resistance may be why such E. faecalis isolates have not been encountered previously. However, specific suggestions for altering currently recommended disk-agar diffusion testing methods (13) to facilitate detection of vancomycin resistance must await investigations that include a greater variety of vancomycin-resistant enterococcal strains. Also needed are evaluations to determine how well various commercial systems, both automated (e.g., AMS Vitek) and nonautomated, detect enterococcal vancomycin resistance.
Finally, because of the resistance that enterococci already exhibit to a variety of antimicrobial agents, the emergence of vancomycin resistance is troublesome. The incidence of this resistance and its impact on the therapeutic management of patients can only be better understood after more in vitro and in vivo studies. Further investigations that enhance our knowledge and understanding of the mechanisms and genetic transferability of this resistance are also needed.
